Top

Molecular Cancer

Published in:

Open Access 01-12-2010 | Research

BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer

Authors: Ali Naderi, Ji Liu, Luke Hughes-Davies

Published in: Molecular Cancer | Issue 1/2010

Abstract

Background

We have previously demonstrated that BEX2 is differentially expressed in breast tumors and has a significant role in promoting cell survival and growth in breast cancer cells. BEX2 expression protects breast cancer cells against mitochondrial apoptosis and G1 cell cycle arrest. In this study we investigated the transcriptional regulation of BEX2 and feedback mechanisms mediating the cellular function of this gene in breast cancer.

Results

We found a marked induction of BEX2 promoter by c-Jun and p65/RelA using luciferase reporter assays in MCF-7 cells. Furthermore, we confirmed the binding of c-Jun and p65/RelA to the BEX2 promoter using a chromatin immunoprecipitation assay. Importantly, transfections of c-Jun or p65/RelA in MCF-7 cells markedly increased the expression of BEX2 protein. Overall, these results demonstrate that BEX2 is a target gene for c-Jun and p65/RelA in breast cancer. These findings were further supported by the presence of a strong correlation between BEX2 and c-Jun expression levels in primary breast tumors. Next we demonstrated that BEX2 has a feedback mechanism with c-Jun and p65/RelA in breast cancer. In this process BEX2 expression is required for the normal phosphorylation of p65 and IκBα, and the activation of p65. Moreover, it is necessary for the phosphorylation of c-Jun and JNK kinase activity in breast cancer cells. Furthermore, using c-Jun stable lines we showed that BEX2 expression is required for c-Jun mediated induction of cyclin D1 and cell proliferation. Importantly, BEX2 down-regulation resulted in a significant increase in PP2A activity in c-Jun stable lines providing a possible underlying mechanism for the regulatory effects of BEX2 on c-Jun and JNK.

Conclusions

This study shows that BEX2 has a functional interplay with c-Jun and p65/RelA in breast cancer. In this process BEX2 is a target gene for c-Jun and p65/RelA and in turn regulates the phosphorylation/activity of these proteins. These suggest that BEX2 is involved in a novel feedback mechanism with significant implications for the biology of breast cancer.

Available only for authorised users

Naderi A, Teschendorff AE, Beigel M, Cariati M, Ellis IO, Brenton JD, Caldas C: BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res. 2007, 67: 6725-6736. 10.1158/0008-5472.CAN-06-4394CrossRefPubMed

Naderi A, Liu J, Bennett IC: BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. Int J Cancer. 2010, 126: 1596-1610.PubMed

Brown AL, Kay GF: Bex1, a gene with increased expression in parthenogenetic embryos, is a member of a novel gene family on the mouse X chromosome. Hum Mol Genet. 1999, 8: 611-619. 10.1093/hmg/8.4.611CrossRefPubMed

Bernstein SL, Koo JH, Slater BJ, Guo Y, Margolis FL: Analysis of optic nerve stroke by retinal Bex expression. Mol Vis. 2006, 1: 147-155.

Hofsli E, Wheeler TE, Langaas M, Laegreid A, Thommesen L: Identification of novel neuroendocrine-specific tumour genes. Br J Cancer. 2008, 99: 1330-1339. 10.1038/sj.bjc.6604565PubMedCentralCrossRefPubMed

Foltz G, Ryu GY, Yoon JG, Nelson T, Fashey J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z: Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res. 2006, 66: 6665-6674. 10.1158/0008-5472.CAN-05-4453CrossRefPubMed

Kim AJ, Lee CS, Schlessinger D: Bex3 associates with replicating mitochondria and is involved in possible growth control of F9 teratocarcinoma cells. Gene. 2004, 343: 79-89. 10.1016/j.gene.2004.08.031CrossRefPubMed

Rohrs S, Dirks WG, Meyer C, Marschalek R, Scherr M, Slany R, Wallace A, Drexler HG, Quentmeier H: Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol Cancer. 2009, 8: 86- 10.1186/1476-4598-8-86PubMedCentralCrossRefPubMed

McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH: The LMO2 T-Cell Oncogene Is Activated via Chromosomal Translocations or Retroviral Insertion during Gene Therapy but Has No Mandatory Role in Normal T-Cell Development. Mol Biol Cell. 2003, 23: 9003-9013. 10.1128/MCB.23.24.9003-9013.2003.CrossRef

10.

Han C, Liu H, Liu J, Yin K, Xie Y, Shen X, Wang Y, Yuan J, Qiang B, Liu YJ, Peng X: Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex. Nucleic Acids Res. 2005, 33: 6555-6565. 10.1093/nar/gki964PubMedCentralCrossRefPubMed

11.

Deng X, Gao F, May WS: Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood. 2009, 113: 422-428. 10.1182/blood-2008-06-165134PubMedCentralCrossRefPubMed

12.

Tsuchiya A, Tashiro E, Yoshiro M, Imoto M: Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1in leptomycin B-inhibited cyclin D1expression. Oncogene. 2007, 16: 1522-1532. 10.1038/sj.onc.1209962.CrossRef

13.

Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Sxzabo E, Zon LI, Kyriakis JM: Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996, 380: 75-79. 10.1038/380075a0CrossRefPubMed

14.

Grether-Beck S, Felsner I, Brenden H, Krutmann J: Mitochondrial Cytochrome c Release Mediates Ceramide-induced Activator Protein 2 Activation and Gene Expression in Keratinocytes. J Biol Chem. 2003, 278: 47498-47507. 10.1074/jbc.M309511200CrossRefPubMed

15.

Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G: Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol. 2002, 64: 963-970. 10.1016/S0006-2952(02)01161-9CrossRefPubMed

16.

Hu J, Haseebuddin M, Young M, Colbum NH: Suppression of p65 phosphorylation coincides with inhibition of IB polyubiquitination and degradation. Mol Carcinog. 2005, 44: 274-284. 10.1002/mc.20142CrossRefPubMed

17.

Demarchi F, Bertoli C, Greer PA, Schneider C: Ceramide triggers an NF-kappaB-dependent survival pathway through calpain. Cell Death Differ. 2005, 12: 512-522. 10.1038/sj.cdd.4401592CrossRefPubMed

18.

Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR: Phosphorylation of c-jun mediated by MAP kinases. Nature. 1991, 353: 670-674. 10.1038/353670a0CrossRefPubMed

19.

Ruvolo PP: Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia. 2001, 15: 1153-1160. 10.1038/sj.leu.2402197CrossRefPubMed

20.

Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ: cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999, 18: 6063-6070. 10.1038/sj.onc.1202989CrossRefPubMed

21.

Wisdom R, Johnson RS, Moore C: c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999, 18: 188-197. 10.1093/emboj/18.1.188PubMedCentralCrossRefPubMed

22.

Seznec J, Weit S, Naumann U: Gene expression profile in a glioma cell line resistant to cell death induced by a the chimeric tumor suppressor-1 (CTS-1), a dominant-positive variant of p53 - the role of NF{kappa}B. Carcinogenesis. 2010, 31: 411-418. 10.1093/carcin/bgp319CrossRefPubMed

23.

Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, Kiss R: Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia. 2009, 11: 485-496.CrossRefPubMed

24.

Jung EJ, Moon HG, Cho BI, Jeong CJ, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW: Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer. 2007, 120: 2331-2338. 10.1002/ijc.22434CrossRefPubMed

25.

Manna SK, Sah NK, Aggarwal BB: Protein tyrosine kinase p56lck is required for ceramide-induced but not tumor necrosis factor-induced activation of NF-kappa B, AP-1, JNK, and apoptosis. J Biol Chem. 2000, 275: 13297-13306. 10.1074/jbc.275.18.13297CrossRefPubMed

26.

Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, Wang Y, Xia LP, Feng GK, Liu QQ: The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene. 2009, 28: 886-898. 10.1038/onc.2008.441CrossRefPubMed

27.

Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, Resar LMS, Birrer MJ: HMG-I/Y is a c-Jun/Activator Protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res. 2004, 2: 305-314.PubMed

28.

Catz SD, Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor B and its significance in prostate cancer. Oncogene. 2001, 20: 7342-7351. 10.1038/sj.onc.1204926CrossRefPubMed

29.

Wang CY, Guttridge DC, mayo MW, Baldwin AS: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999, 19: 5923-5929.PubMedCentralCrossRefPubMed

30.

Huber MA, Denk A, Peter RU, Weber L, Kraut N, Wirth T: The IKK-2/Ikappa Balpha/NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice. J Biol Chem. 2002, 277: 1268-1275. 10.1074/jbc.M109358200CrossRefPubMed

31.

Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Listanti MP, Pestell RG: c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem. 2010, 285: 8218-8226. 10.1074/jbc.M110.100792PubMedCentralCrossRefPubMed

32.

Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ: NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med. 2007, 13: 62-69. 10.1038/nm1519CrossRefPubMed

33.

Shen Q, Uray IP, Li Y, Krisko tI, Strecker TE, Kim HT, Brown PH: The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2007, 27: 366-377. 10.1038/sj.onc.1210643CrossRefPubMed

34.

Yang J, Fan GH, Wadzinski BE, Sakurai H, Richmond A: Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001, 276: 47828-47833.PubMedCentralPubMed

35.

Barisic S, Strozyk E, Peters N, Walczak H, Kulms D: Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ. 2008, 15: 1681-1690. 10.1038/cdd.2008.98CrossRefPubMed

36.

Kins S, Kurosinski P, Nitsch RM, Gotz J: Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol. 2003, 163: 833-843.PubMedCentralCrossRefPubMed

37.

Tan Y, Rouse J, Zhang A, Cariati S, Cohen P, Comb MJ: FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J. 1996, 15: 4629-4642.PubMedCentralPubMed

38.

Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, Yuan G, Zhang H, Yu M, Hu M: Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer. 2007, 7: 145- 10.1186/1471-2407-7-145PubMedCentralCrossRefPubMed

39.

Begum N, Ragolia L: cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells. J Biol Chem. 1996, 271: 31166-31171. 10.1074/jbc.271.49.31166CrossRefPubMed

40.

Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe JE, Robertson JE, Aparicio S, Ellis IO, Brenton JD, Caldas C: A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2007, 26: 1507-1516. 10.1038/sj.onc.1209920CrossRefPubMed

Title: BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer
Authors: Ali Naderi
Ji Liu
Luke Hughes-Davies
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-9-111

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1

Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer

P-cadherin counteracts myosin II-B function: implications in melanoma progression

Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene

Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid

Characterization of the role of the tumor marker Nup88 in mitosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer